Leica Biosystems announced on August 11, 2026 a batch of new FDA 510(k) clearances for its digital pathology portfolio, headlined by what the company calls the industry’s first standalone, FDA-cleared software for AI-assisted quality control in a clinical pathology setting. Rather than helping diagnose disease directly, the new tool, Aperio iQC DX, is aimed at a quieter but foundational problem: catching the technical flaws that creep into digital pathology slides before they ever reach a pathologist’s screen.
The Problem: Bad Slides In, Bad Diagnoses Out
Digital pathology depends on converting physical glass slides into high-resolution digital images, a process with plenty of opportunity for error. Air bubbles trapped under the coverslip, stray pen marks, tissue that gets clipped or goes missing during processing, regions that come out of focus, and image striping introduced during scanning can all degrade a slide in ways that are easy for a busy histotechnician to miss but that can meaningfully affect a pathologist’s ability to make an accurate read. Aperio iQC DX is designed specifically to catch these six categories of artifact automatically, before a case is ever routed to a pathologist for review.
The Validation Numbers
In a real-world study conducted with the Institute of Pathology at Heidelberg University, Leica’s AI models detected up to 24% more artifacts than histotechnicians caught on their own, while also delivering a 69% reduction in the hands-on review time needed to check slide quality. That combination, catching more errors while requiring less manual labor, is the pitch Leica is making to pathology labs already stretched thin by staffing shortages and rising slide volumes.
New Hardware Alongside the Software
The same batch of clearances also introduced the Aperio GT 180 DX, a new digital pathology scanner aimed at mid-volume labs with a 180-slide capacity, while extending capabilities for the higher-throughput Aperio GT 450 DX scanner already on the market. Together, the announcements represent Leica doubling down on a full-stack digital pathology strategy, pairing its scanner hardware with AI software layered on top, rather than selling either piece in isolation.
Why Quality Control AI Is a Different Kind of Clearance
The Case for Skepticism
Quality-control software still requires labs to trust a second layer of AI judgment: false positives that flag acceptable slides as flawed can slow down lab throughput and offset the promised time savings, while false negatives that miss real artifacts undercut the entire premise of the tool. The 24% improvement figure comes from a single academic validation site in Heidelberg, and pathology labs adopting the software elsewhere will need to confirm similar performance gains hold up across their own scanner models, staining protocols, and tissue types before fully relying on it to replace manual quality checks.
What’s Next
Leica’s move suggests that as digital pathology AI proliferates, quality assurance for the images feeding those algorithms is emerging as its own product category, not just an afterthought bolted onto diagnostic tools. Expect competing scanner and software vendors to pursue similar quality-control clearances as labs increasingly demand assurance that the digital images underpinning both human and AI diagnostic reads meet a consistent technical bar before any diagnosis, human or algorithmic, gets made on top of them.
